Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arexvy in immunocompromised adults
2024-513187-25-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of GSK3003899A in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Fold increase of RSV-A and RSV-B neutralizing titers after second dose versus after first dose. Planned start Sep 2024; status: authorised.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-513187-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513187-25-00.